Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ASCO 2026: serial Signatera positivity after week 12 tracked with worse outcomes on enfortumab vedotin

In 110 patients with advanced urothelial carcinoma treated with enfortumab vedotin with or without pembrolizumab, an ASCO 2026 analysis of serial Signatera testing associated ctDNA positivity after 12 weeks with worse progression-free survival (HR 36.8) and overall survival (HR 17.7).

Journal of Clinical Oncology